drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
Anti-CD2 monoclonal antibody (also known as TCD601) used peri-transplant for in vivo T-cell depletion to reduce GVHD and graft failure; targets CD2 on T and NK cells.
nci_thesaurus_concept_id
C38685
nci_thesaurus_definition
A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.
drug_mesh_term
Siplizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti‑CD2 monoclonal antibody that binds CD2 on T and NK cells and induces immune‑mediated cytotoxicity (ADCC/CDC), depleting CD2+ lymphocytes and suppressing T‑cell activity to reduce GVHD and graft rejection.
drug_name
Siplizumab
nct_id_drug_ref
NCT06078696